Bremelanotide rescued erectile function in 33.5% of sildenafil non-responders
Background
Erectile dysfunction (ED) affects a broad population of men, and phosphodiesterase-5 inhibitors such as sildenafil represent the dominant first-line pharmacological standard of care. However, a clinically significant subset of patients fails to respond to sildenafil, leaving them without an effective oral option and generating an unmet therapeutic need. Bremelanotide (PT-141) is a synthetic melanocortin peptide that acts centrally via MC3R/MC4R receptors in the hypothalamus to potentiate sexual arousal through a nitric-oxide-independent pathway — mechanistically distinct from PDE5 inhibition. This central mechanism makes it a rational candidate specifically for men whose ED does not originate from peripheral vascular insufficiency alone and who have already exhausted first-line therapy.
Study Design
A randomized, double-blind, placebo-controlled trial enrolled 342 married men aged 28–59 with confirmed ED who had failed sildenafil. Participants were assigned to 10 mg intranasal bremelanotide spray (n=172) or matched placebo (n=170), self-administered 45 minutes to 2 hours before sexual stimulation. The protocol required at least 16 doses/attempts at home. Primary endpoints were assessed via the International Index of Erectile Function (IIEF) every 4 attempts and at end of study, with secondary measures including mean intercourse satisfaction domain score, mean weekly coitus episodes, and adverse drug effects.
Results
Bremelanotide produced positive clinical outcomes in 51 of 172 (33.5%) patients compared with 13 of 170 (8.5%) in the placebo group.
Bremelanotide responder rate was 33.5% vs 8.5% placebo — a nearly 4-fold difference — with a between-group significance of p = 0.03.
Intercourse satisfaction domain scores on the IIEF were significantly higher in the bremelanotide arm versus placebo (p = 0.03). Drug-related adverse effects were more frequent in the bremelanotide group relative to placebo (p = 0.01), indicating a tolerability signal that warrants attention. The authors note that both the 33.5% response rate and the intercourse satisfaction advantage support the biological plausibility of centrally acting MC4R-mediated arousal pathways in this refractory population, though the absolute response rate also underscores that the majority of even sildenafil non-responders did not achieve clinical benefit at this dose and regimen.
Key Findings
- Bremelanotide responder rate: 33.5% (51/172) vs placebo 8.5% (13/170), p=0.03
- Intercourse satisfaction domain significantly greater in bremelanotide arm (p=0.03)
- Drug-related adverse effects significantly more frequent in bremelanotide group (p=0.01)
- Dose used: 10 mg intranasal spray, 45 min–2 hours pre-activity, minimum 16 attempts
- Population: 342 married men aged 28–59 with confirmed sildenafil non-response
Why It Matters
Clinicians managing sildenafil non-responders now have preliminary randomized evidence for a mechanistically distinct intranasal peptide option. Because bremelanotide acts centrally via MC3R/MC4R rather than through peripheral PDE5 inhibition, it may address ED etiologies that are not vascular in origin — a population routinely excluded from benefit by current first-line agents. For practitioners and informed users, the 45-minute to 2-hour pre-activity dosing window and intranasal delivery route are practically significant: they differ from oral PDE5 inhibitors in onset flexibility. The authors explicitly call for studies with different dosages and regimens before a definitive protocol can be established, meaning the 10 mg intranasal dose used here should not yet be treated as an optimized clinical standard.
TitrateLab articles covering PT-141
Written by TitrateLab, separately from the study summarized above.
